Retraction
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors
Paper Information
Record ID:
44402
Author(s):
Journal:
Publication Date:
July 10, 2010
Retraction Date:
May 09, 2023
(2.5 years years ago)
Subjects:
Institutions:
- Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale “F. Magrassi e A. Lanzara”, Seconda Università degli Studi di Napoli, Via S. Pansini 5, 80131 Naples, Italy
- Immunologia Clinica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale “F. Magrassi e A. Lanzara”, Seconda Università degli Studi di Napoli, Via S. Pansini 5, 80131 Naples, Italy
Country:
🇮🇹 ItalyArticle Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1016/j.lungcan.2023.107226Citations (32)
32
Total Citations2
Post-Retraction(6.3%)
30
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
2
Within 1 year
0
After 2+ years
44
Days since retraction (latest)
Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics
Iqrar Ahmad, Bimal Debnath, Saikat Kar et al. (7 authors)
Journal of Biomolecular Structure and Dynamics
Open Access
Published: Jun 2023
9 citations
9 citations
44 days after retraction
Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors
Mehdi Sanati, Amir R. Afshari, Seyed Sajad Ahmadi et al. (5 authors)
BioFactors
Published: May 2023
5 citations
5 citations
1 days after retraction
Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
Maria Maddalena Laterza, Vincenza Ciaramella, Bianca Arianna Facchini et al. (14 authors)
Cancers
Open Access
Published: May 2021
6 citations
6 citations
727 days before retraction
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression
Fang Yang, Wangwang Liu, Hui Chen et al. (9 authors)
Journal of Zhejiang University SCIENCE B
Open Access
Published: Dec 2019
11 citations
11 citations
1235 days before retraction
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells
Vincenza Ciaramella, Carminia Maria Della Corte, Concetta Di Mauro et al. (14 authors)
Oncotarget
Open Access
Published: Apr 2018
10 citations
10 citations
1856 days before retraction
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells
Linda Sooman, Joachim Gullbo, Michael Bergqvist et al. (6 authors)
BMC Research Notes
Open Access
Published: Nov 2017
20 citations
20 citations
2014 days before retraction
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
Floriana Morgillo, Carminia Maria Della Corte, Anna Diana et al. (13 authors)
Oncotarget
Open Access
Published: Aug 2017
27 citations
27 citations
2086 days before retraction
Paper citing Antitumor activity of bortezomib in human cancer c...
Unknown Authors
Unknown Journal
Published: Aug 2017
2086 days before retraction
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
Carminia Maria Della Corte, Umberto Malapelle, Elena Vigliar et al. (11 authors)
Oncotarget
Open Access
Published: Feb 2017
36 citations
36 citations
2271 days before retraction
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
Teru Hideshima, Jun Qi, Ronald M. Paranal et al. (21 authors)
Proceedings of the National Academy of Sciences
Open Access
Published: Oct 2016
131 citations
131 citations
2381 days before retraction
Predictive Modeling of Drug Effects on Signaling Pathways in Diverse Cancer Cell Lines
Shital Kumar Mishra, Sourav S. Bhowmick, Huey Eng Chua et al. (4 authors)
Unknown Journal
Published: Oct 2016
2410 days before retraction
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
Shuliang Liu, Yang Hong-ji, Xingping Ge et al. (6 authors)
Oncology Letters
Open Access
Published: Sep 2016
14 citations
14 citations
2420 days before retraction
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
Luigi Formisano, Valentina Damato, Alberto Servetto et al. (16 authors)
Oncotarget
Open Access
Published: Aug 2015
39 citations
39 citations
2836 days before retraction
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Amanda F. Baker, Neale T. Hanke, Barbara J. Sands et al. (6 authors)
Journal of Experimental & Clinical Cancer Research
Open Access
Published: Dec 2014
38 citations
38 citations
3081 days before retraction
Follistatin Is a Novel Biomarker for Lung Adenocarcinoma in Humans
Fangfang Chen, Ping Ren, Feng Ye et al. (8 authors)
PLoS ONE
Open Access
Published: Oct 2014
18 citations
18 citations
3116 days before retraction
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells
J.-Z. Hou, Anguo Cui, Peiying Song et al. (6 authors)
Molecular Medicine Reports
Open Access
Published: Oct 2014
24 citations
24 citations
3121 days before retraction
Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line
Rafał Krętowski, Anna Stypułkowska, Marzanna Cechowska‐Pasko
Molecular and Cellular Biochemistry
Open Access
Published: Oct 2014
20 citations
20 citations
3136 days before retraction
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231
Rafał Krętowski, Małgorzata Borzym‐Κluczyk, Marzanna Cechowska‐Pasko
Molecular and Cellular Biochemistry
Open Access
Published: Jan 2014
21 citations
21 citations
3414 days before retraction
Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
Rafał Krętowski, Małgorzata Borzym‐Κluczyk, Marzanna Cechowska‐Pasko
BioMed Research International
Open Access
Published: Jan 2014
9 citations
9 citations
3415 days before retraction
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
Panagiotis J. Vlachostergios, Ioannis A. Voutsadakis, Christos N. Papandreou
Cell Biology and Toxicology
Published: Jun 2013
10 citations
10 citations
3627 days before retraction
Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Wendy Xolalpa, Patricia Pérez‐Galán, Manuel S. Rodríguez et al. (4 authors)
Current Pharmaceutical Design
Published: May 2013
29 citations
29 citations
3660 days before retraction
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
Man Zou, Shu Xia, Liang Zhuang et al. (10 authors)
International Journal of Oncology
Open Access
Published: Apr 2013
28 citations
28 citations
3679 days before retraction
Paper citing Antitumor activity of bortezomib in human cancer c...
Unknown Authors
Unknown Journal
Published: Sep 2012
3902 days before retraction
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
Shigeru Kawabata, Joell J. Gills, J R Mercado-Matos et al. (7 authors)
Cell Death and Disease
Open Access
Published: Jul 2012
71 citations
71 citations
3946 days before retraction
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
Michael J. Lee, Albert S. Ye, Alexandra K. Gardino et al. (7 authors)
Cell
Open Access
Published: May 2012
663 citations
663 citations
4025 days before retraction
Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Floriana Morgillo, Erika Martinelli, Teresa Troiani et al. (6 authors)
PLoS ONE
Open Access
Published: Dec 2011
43 citations
43 citations
4169 days before retraction
Mechanisms of acquired resistance to tyrosine kinase inhibitors
Yifan Chen, Liwu Fu
Acta Pharmaceutica Sinica B
Open Access
Published: Nov 2011
84 citations
84 citations
4190 days before retraction
The 26S proteasome complex: An attractive target for cancer therapy
Sarah Frankland‐Searby, Sukesh R. Bhaumik
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Open Access
Published: Oct 2011
174 citations
174 citations
4219 days before retraction
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
Floriana Morgillo, Tina Cascone, Elena D’Aiuto et al. (11 authors)
British Journal of Cancer
Open Access
Published: Jul 2011
53 citations
53 citations
4330 days before retraction
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review
Mark P. Murphy, Britta Stordal
Drug Resistance Updates
Published: Mar 2011
59 citations
59 citations
4428 days before retraction
Proteasome inhibitors in cancer therapy
Lisa Crawford, Brian Walker, Alexandra E. Irvine
Journal of Cell Communication and Signaling
Open Access
Published: Jan 2011
291 citations
291 citations
4483 days before retraction
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Mohammad Shahshahan, Maureen N Beckley, Ali R. Jazirehi
PubMed
Published: Jan 2011
38 citations
38 citations
4511 days before retraction
Quick Stats
Total Citations:
32
Years Since Retraction:
2.5 years
Open Access:
Yes
Last Checked:
Jul 24, 2025